Program       June 22, 9:00am – 12:00 noon (ET)

9:00 am  Welcome and Introductions
         Chairs: Linda Klavinskis & Shan Lu, ISV

Opening Session (20 min talks + 5 min Q&A)
Overview, Chair: Shan Lu, ISV
9:05am    Kwok-Yung Yuen, The University of Hong Kong
          Overview of COVID-19
9:30am    Nick Jackson, CEPI
          Overview of COVID-19 vaccine development

Scientific Session One (18 min talks + 7 min Q&A)
Nucleic Acid Vaccines, Chair: Margaret Liu, ISV
9:55am    Kate Broderick, Inovio Pharmaceuticals
          Advantages of a DNA-based Approach to the
          Development of a COVID-19 Vaccine
10:20am   Barney Graham (VRC/NIAID/NIH)
          Rapid COVID-19 Vaccine Development Enabled
          by Prototype Pathogen Preparedness

Viral Vector Vaccines, Chair: Linda Klavinskis, ISV
10:45am   Sarah Gilbert, University of Oxford
          Rapid Progress with Development of ChAdOx1
          nCoV-19
11:10am   Tao Zhu, CanSino Biological
          Development of Adenovirus Vector based
          COVID-19 Vaccine

Scientific Session Two (25 min panel discussion)
Challenges for COVID-19 vaccines development
Moderator: David Weiner, ISV
11:35am   Peter Openshaw, Imperial College London
          Stanley Perlman, University of Iowa
          Stanley Plotkin, VaxConsult
          - Are human challenge studies acceptable?
          - Safety concerns and suboptimal antibody responses

Wrap up and announcement of 2nd ISV Virtual Congress on COVID-19 Vaccines
12 noon  Closing remarks
         Margaret Liu, ISV

The virtual congress will be run by Microsoft Teams.
Program  July 21, 9:00am – 12:00PM (ET)
9:00 am  Welcome and Introductions
Chair: Shan Lu, UMass Medical School/ISV
Linda Klavinskis, King’s College London/ISV
Introduction of ISV Virtual Congress

Opening Session (20 min talks + 5 min Q&A)
Chair: Denise Doolan, James Cook University/ISV
9:05am Larry Corey, Fred Hutchinson Cancer Res. Center
COVID Vaccine Planning: The USG Approach
9:30am Marion Gruber, US FDA
Regulatory Considerations in the Development
and Licensure of COVID-19 Vaccines

Scientific Session One (18 min talks + 7 min Q&A)

Part I: Protein and Inactivated Vaccines
Chair: Manon Cox, NextWaveBio/ISV
9:55am Greg Glenn, Novavax
Progress with the Full Length Recombinant Spike
Protein Nanoparticle Vaccine
10:20am George Gao, China CDC
Development of Inactivated COVID-19 Vaccines

Part II: Viral Vector and RNA Vaccines
Chair: Linda Klavinskis, King’s College London/ISV
10:45am Hanneke Schuitemaker, J&J/Janssen
The Development of an Ad26-based
SARS-CoV-2 Vaccine
11:10am Kena Swanson, Pfizer
RNA Based COVID-19 Vaccines

Scientific Session Two (25 min panel discussion)
Challenges for COVID-19 Vaccines Development:
The Roles of Animal Models
Moderator: Stanley Perlman, University of Iowa
11:35am Bart Haagmans, Erasmus University
Vincent Munster, RML/NIH
Linda Saif, The Ohio State University

Wrap up and Announcement of 3rd ISV Virtual
Congress on COVID-19 Vaccines
12:00PM  Shan Lu, ISV
Program  Aug 25, 9:00am – 12:00 noon (ET)

9:00 am  Welcome and Introductions
Chair: Shan Lu, UMass Medical School/ISV
Linda Klavinskis, King’s College London/ISV
Introduction of ISV Virtual Congress

Opening Session (20 min talks + 5 min Q&A)
Chair: Shan Lu, ISV
9:05am  Myron Cohen, UNC-Chapel Hill
mAbs for COVID-19: Treatment and Prevention
9:30am  Lynda Stuart, Bill & Melinda Gates Foundation
COVID-19 Vaccine: How We Win the Race to Billions of Doses

Scientific Session One (18 min talks + 7 min Q&A)
Part I: Protein Vaccines
Chair: Xavier Saelens, University of Ghent/ISV
9:55am  Keith Chappell, The University of Queensland
Molecular Clamp Stabilized Recombinant Protein Subunit Vaccine for COVID-19
10:20am  John Shiver, Sanofi-GSK
Recombinant and mRNA Vaccine Candidates Against COVID-19

Part II: Novel Vaccine Technologies
Chair: Anna-Lise Williamson, University of Cape Town/ISV
10:45am  Jacqueline Miller, Moderna
Modernas Coronavirus Vaccine: Early Clinical Data and the COVE Phase III Efficacy and Safety Study
11:05am  Brian Ward, Medicago
Development of Plant-Derived SARS-CoV-2 Virus-Like Particle (CoVLP) Vaccine

Scientific Session Two (30 min panel discussion)
The Role of T and B Cell Responses and Vaccine Assay Standards for Determining Efficacy
Moderator: Margret Liu, ProTherImmune/ISV
11:30am  Alessandro Sette, La Jolla Institute for Immunology
Michel Nussenzweig, The Rockefeller University
Neil Almond, NIBSC

Wrap up and Future ISV Virtual Congresses
12:00pm  Linda Klavinskis, ISV
February 10, 2021 – 11:35am (ET)

Welcome and Introductions
Chair: Shan Lu, UMass Medical School/ISV
Introduction: Linda Klavinskis, King’s College London/ISV

Session One: Adeno Viral Vector Vaccines
Chair: Linda Klavinskis, ISV
9:00am Inna Dolzhikova, Gamaleya National Research Center for Epidemiology and Microbiology
Safety and Efficacy of Sputnik V Vaccine: An Interim Analysis of Phase 3 Trial in Russia
9:30am Sarah Gilbert, Oxford University/AZ
Pandemic Vaccine Development During a Pandemic

Session Two: mRNA Vaccines
Chair: Margaret Liu, ProTherImmune/ISV
10:00am Kathrin Jansen, Pfizer
Efficacy Data Updates from the Pfizer-BioNTech mRNA Vaccine Candidate
10:30am Jacqueline Miller, Moderna
Overview of the Moderna COVID-19 Vaccine (mRNA-1273)

Session Three: Post-Authorization Safety Surveillance
Chair: Shan Lu, ISV
11:00am Tom Shimabukuro, US CDC
COVID-19 Vaccine Safety Update, United States

Wrap up and Future ISV Virtual Congresses
11:30am Shan Lu, ISV

Congress Advisors
Yiwu He, The University of Hong Kong (HKU)
Nick Jackson, The Coalition for Epidemic Preparedness Innovations (CEPI)
Merlin Robb, U.S. Military HIV Research Program (MHRP)
Nina Russel, Bill & Melinda Gates Foundation (BMGF)
Scientific Program

April 28, 8:30 am – 10:20 am (Beijing time)

8:30am Welcome and Introductions
Chair: Shan Lu, U Mass Medical School/ISV
Introduction Denise Doolan, President-Elect ISV

Session One: Adenoviral Vector Based Vaccine
Chair: Denise Doolan, James Cook University/ISV
8:40am Jinbo Gou, CanSino Biological
Updates on Recombinant Adenovirus 5 vector based COVID-19 Vaccine (Ad5-nCoV)

Session Two: Inactivated Vaccines
Chair: Joon Rhee, Chonnam Nat. Uni Med School/ISV
9:10am Meng Li
Sinopharm CNBG
Phase III Study of Inactivated COVID-19 Vaccine
9:40am Weining Meng
Sinovac Biotech Co., Ltd.
Phase III Clinical and Real-World Data of Inactivated COVID-19 Vaccine

Wrap up and Future ISV Virtual Congresses
10:10am Shan Lu, U Mass Medical School/ISV

Congress Advisors
Yiwu He, University of Hong Kong (HKU)
Nick Jackson, Coalition for Epidemic Preparedness Innovations (CEPI)

April 28, 2021
Sydney 10:30 am
Seoul/Tokyo 9:30 am
Beijing 8:30 am
New Delhi 6:30am
Frankfurt 2:30am
London 1:30 am

April 27, 2021
New York 8:30pm
Los Angeles 5:30pm
Scientific Program
May 25, 9:00AM – 11:35AM (EDT)

9:00am Welcome and Introductions
Chair: Shan Lu, U Mass Medical School/ISV
Introduction Linda Klavinskis, King’s College London/ISV

Session One: Adeno Vector COVID-19 Vaccine Update
Chair: Linda Klavinskis, King’s College London/ISV
9:10am Hanneke Schuitemaker, Janssen Vaccines & Prevention B.V.
Janssen’s Effort in the Development of a COVID-19 Vaccine

Session Two: Recombinant Protein COVID-19 Vaccine Update
Chair: Margaret Liu, ProTherImmune/ISV
9:50am Greg Glenn, Novavax, Inc.
COVID-19 Program Update

Session Three: Vaccine Variants
Chair: Shan Lu, U Mass Medical School/ISV
10:30am Pei-Yong Shi, U of Texas Medical Branch
SARS-CoV-2 Variants and Antibody Neutralization

Session Four: Vaccine Safety
Chair: Shan Lu, U Mass Medical School/ISV
11:00am Mariana Castells, Brigham and Women’s Hospital
COVID-19 mRNA Vaccine Safety: Local and Systemic Hypersensitivity

Wrap Up and Future ISV Virtual Congresses
11:30am Margaret Liu, ProTherImmune/ISV

Congress Advisors
Nick Jackson, Coalition for Epidemic Preparedness Innovations (CEPI)

May 25, 2021
New York 9:00 am
Los Angeles 6:00 am
London 2:00 pm
Frankfurt 3:00 pm
Beijing 9:00 pm
Seoul/Tokyo 10:00 pm